Last reviewed · How we verify
NCT04738552
A Study of Detection of Paroxysmal Events Utilizing Computer Vision and Machine Learning
trial testing Nelli in Epilepsy in 233 participants. Completed in 27 November 2022.
27 November 2022
Quick facts
| Lead sponsor | Neuro Event Labs Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 233 |
| Start date | 9 January 2020 |
| Primary completion | 27 November 2022 |
| Estimated completion | 27 November 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Nelli
Conditions studied
- Epilepsy — all drugs for Epilepsy →
Sponsor
Neuro Event Labs Inc.
Who can join
Adults 18 to 99, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Increased computational power has made it possible to implement complex image recognition tasks and machine learning to be implemented in every day usage. The computer vision and machine learning based solution used in this project (Nelli) is an automatic seizure detection and reporting method that has a CE mark for this specific use. The present study will provide data to expand the utility and detection capability of NELLI and enhance the accuracy and clinical utility of automated computer vision and machine learning based seizure detection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04738552
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nelli
Trials testing the same drug.
- NCT06705439 — A Study of Detection of Paroxysmal Events Utilizing Computer Vision and Machine Learning (USF) · completed
- NCT05606575 — A Study of Detection of Paroxysmal Events Utilizing Computer Vision and Machine Learning - Nelli · completed
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other Neuro Event Labs Inc. trials
Trials by the same sponsor.
- NCT06705439 — A Study of Detection of Paroxysmal Events Utilizing Computer Vision and Machine Learning (USF) · completed
- NCT05606575 — A Study of Detection of Paroxysmal Events Utilizing Computer Vision and Machine Learning - Nelli · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04738552 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Neuro Event Labs Inc.
- Last refreshed: 25 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04738552.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing